Immunogenicity of BRCA1-deficient ovarian cancers is driven through DNA sensing and is augmented by PARP inhibition

被引：0
|
作者：
Bruand, M. [1 ]
Barras, D. [1 ,2 ]
Mina, M. [3 ]
Lanitis, E. [1 ]
Chong, C. [1 ]
Dorier, J. [2 ]
Walton, J. [4 ]
Bassani-Sternberg, M. [1 ]
Kandalaft, L. [1 ]
McNeish, I. A. [5 ]
Swisher, E. [6 ]
Delorenzi, M. [1 ]
Ren, B. [7 ,8 ]
Ciriello, G. [3 ]
Irving, M. [1 ]
Rusakiewicz, S. [1 ]
Foukas, P. [1 ]
Martinon, F. [9 ]
Dangaj, D. [1 ]
Coukos, G. [1 ]
机构：
[1] Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol, Epalinges, Switzerland
[2] Univ Lausanne, Vital IT, Swiss Inst Bioinformat SIB, Epalinges, Switzerland
[3] Univ Lausanne, Dept Computat Biol, Lausanne, Switzerland
[4] Imperial Coll London, Dept Surg & Canc, Ovarian Canc Act Res Ctr, Hammersmith Hosp, London, England
[5] Imperial Coll London, Dept Surg & Canc, London, England
[6] Univ Washington, Seattle Canc Care Alliance, Med, Seattle, WA 98195 USA
[7] Ludwig Inst Canc Res, San Diego Sch Med, Dept Cellular & Mol Med, Inst Genom Med, La Jolla, CA USA
[8] Univ Calif San Diego, La Jolla, CA 92093 USA
[9] Univ Lausanne, Dept Biochem, Lausanne, Switzerland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1876PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EXO1 protects BRCA1-deficient cells against toxic DNA lesions
    van de Kooij, Bert
    Schreuder, Anne
    Pavani, Raphael
    Garzero, Veronica
    Uruci, Sidrit
    Wendel, Tiemen J.
    Hoeck, Arne van
    Alonso, Marta San Martin
    Everts, Marieke
    Koerse, Dana
    Callen, Elsa
    Boom, Jasper
    Mei, Hailiang
    Cuppen, Edwin
    Luijsterburg, Martijn S.
    van Vugt, Marcel A. T. M.
    Nussenzweig, Andre
    van Attikum, Haico
    Noordermeer, Sylvie M.
    MOLECULAR CELL, 2024, 84 (04) : 659 - 674.e7
  • [32] Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells
    Farkkila, Anniina
    Rodriguez, Alfredo
    Oikkonen, Jaana
    Gulhan, Doga C.
    Huy Nguyen
    Dominguez, Julieta
    Ramos, Sandra
    Mills, Caitlin E.
    Perez-Villatoro, Fernando
    Lazaro, Jean-Bernard
    Zhou, Jia
    Clairmont, Connor S.
    Moreau, Lisa A.
    Park, Peter J.
    Sorger, Peter K.
    Hautaniemi, Sampsa
    Frias, Sara
    D'Andrea, Alan D.
    CANCER RESEARCH, 2021, 81 (10) : 2774 - 2787
  • [33] Combining PD1-and CTLA4-inhibiting antibodies with cisplatin or PARP inhibition in an attempt to eradicate BRCA1-deficient mouse mammary tumors
    Blatter, Sohvi
    Guyader, Charlotte
    Kucukosmanoglu, Asli
    Freriks, Stephan
    de Visser, Karin
    Borst, Piet
    Rottenberg, Sven
    CANCER RESEARCH, 2015, 75
  • [34] Upregulation of STAT3 signaling in tumor cells fosters a TME-dependent secondary resistance of BRCA1-deficient HGSOC to PARP inhibition
    Ding, Liya
    Wang, Qiwei
    Kearns, Michael
    Jiang, Tao
    Cheng, Xin
    Qian, Changli
    Zhao, Jean
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
    Dedes, Konstantin J.
    Wilkerson, Paul M.
    Wetterskog, Daniel
    Weigelt, Britta
    Ashworth, Alan
    Reis-Filho, Jorge S.
    CELL CYCLE, 2011, 10 (08) : 1192 - 1199
  • [36] Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
    Xie, Xuexia
    Chen, Congcong
    Wang, Cong
    Guo, Yongjian
    Sun, Binghe
    Tian, Jiaxin
    Yan, Jin
    Li, Dake
    Chen, Guo
    REDOX BIOLOGY, 2024, 76
  • [37] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
    Di Zhang
    Bijay Singh
    Jessica Moerland
    Owen Mitchell
    Lizbeth Lockwood
    Sarah Carapellucci
    Srinivas Sridhar
    Karen T. Liby
    Scientific Reports, 11
  • [38] The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice
    To, Ciric
    Kim, Eun-Hee
    Royce, Darlene B.
    Williams, Charlotte R.
    Collins, Ryan M.
    Risingsong, Renee
    Sporn, Michael B.
    Liby, Karen T.
    CANCER PREVENTION RESEARCH, 2014, 7 (07) : 698 - 707
  • [39] Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition
    Zhang, Haipeng
    Yu, Na
    Chen, Yan
    Yan, Kaowen
    Wang, Xiaozhen
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (08) : 13037 - 13045
  • [40] Global analysis of differentially expressed genes in BRCA1-deficient murine ovarian cancer cell lines
    Lang, Jennifer
    Xing, Deyin
    Orsulic, Sandra
    CANCER RESEARCH, 2009, 69
12345